

Application Data Sheet

No.46

GC-MS

Gas Chromatograph - Mass Spectrometer

Analysis of Potential Genotoxic Impurities in Active Pharmaceutical Ingredients (5) - Analysis of Alkyl Halides -

Alkyl halides are used as an alkylating agent for raw ingredients in the synthesis of pharmaceuticals or are generated as a byproduct of drug synthesis. They have been identified as potential carcinogens or genotoxins. This Application Data Sheet shows an example of analyzing 18 alkyl halides using headspace-GC-MS.

Experimental

Standard mixtures were prepared by diluting 18 types of alkyl halides in methanol to 0.2, 2, 10, 20, and 100 µg/mL concentrations. An internal standard solution was prepared by diluting fluorobenzene in methanol to a 20 µg/mL concentration. Test samples were prepared by placing 20 mg of the pharmaceutical ingredients in a 20 mL screw-cap vial (La-Pha-Pack P/N: 18 09 1307), diluting it with 10 mL of Milli-Q water, adding 10 µL of the internal standard solution, and then quickly sealing the vial by screwing on the magnetic screw-cap (La-Pha-Pack P/N: 18 09 1309). Standard aqueous samples were prepared by adding 10 µL of each standard alkali halide mixture and 10 µL of the internal standard solution to 10 mL Milli-Q water. The concentrations of the prepared standard aqueous samples were 0.2, 2, 10, 20, and 100 ng/mL (equivalent to 0.1, 1, 5, 10, and 50 ng/mg concentrations in the active pharmaceutical ingredients), respectively.

Analytical Conditions

FASST (Fast Automated Scan/SIM Type), which is capable of simultaneous Scan and SIM measurements, was used as the measurement mode. The analysis conditions are shown in Table 1.

Table 1: Analytical Conditions

GC-MS	:GCMS-QP2010 Ultra		
Autosampler	:AOC-5000 Plus (HS)		
Column	:Rtx-1 (60 m length, 0.25 mm I.D., df=1.0 µm)		
Glass Insert	:Deactivated Split insert with wool (PN: 225-20803-01)		
[AOC-5000 Plus (HS)]		[GC]	
Incubation Temp.	:80 °C	Injection Temp.	:230 °C
Incubation Time	:30 min	Column Oven Temp.	:40 °C (2 min) → (20 °C/min) → 250 °C (4 min)
Syringe Temp.	:100 °C	Injection Mode	:Split
Agitator Speed	:250 rpm	Carrier Gas	:Helium
Fill Speed	:500 µL/sec	Flow Control Mode	:Linear velocity (25.5 cm/sec)
Pull Up Delay	:500 msec	Split Ratio	:10
Inject to	:GC Inj 1	[MS]	
Injection Speed	:500 µL/sec	Interface Temp.	:230 °C
Pre Inject Delay	:500 msec	Ion source Temp.	:230 °C
Flush Time	:5 min	Tuning Mode	:High sensitivity
GC Run Time	:25 min	Measurement mode	:FASST (simultaneous Scan/SIM measurements)
Injection Volume	:1 mL	Scan Mass Range	:m/z 30 - 270
SIM Monitoring m/z:		Scan Event Time	:0.05 sec
Chloromethane	50, 52	Scan Speed	:10,000 u/sec
Vinyl chloride	62, 64	SIM Event Time	:0.3 sec
2-Chloropropane	43, 78	1-Bromopropane	43, 122
Iodomethane	142, 127	2-Iodopropane	43, 170
1-Chloropropane	42, 78	Fluorobenzene	96, 70
trans-1,2-Dichloroethylene	61, 96	1-Bromo-2-methylpropene	55, 134
2-Bromopropane	43, 122	1-Iodopropane	43, 170
cis-Dichloroethylene	61, 96	trans-1,2-Dibromoethylene	186, 105
2-Chloroacrylonitrile	87, 52	cis-1,2-Dibromoethylene	186, 105
1-Chloro-2-methylpropene	55, 90	trans-3-Bromo-2-methylacrylonitrile	66, 145
		cis-3-Bromo-2-methylacrylonitrile	66, 145

Results

The total ion current chromatogram for the 100 ng/mL concentration standard aqueous solution (equivalent to 50 ng/mg concentration* in the active pharmaceutical ingredients) is shown in Fig. 3. The SIM chromatograms for six typical components in the 0.2 ng/mL concentration standard aqueous solution (equivalent to 0.1 ng/mg concentration* in the pharmaceutical) are shown in Fig. 4.

* 1,2-Dibromoethylene and 3-Bromo-2-methylacrylonitrile concentrations include both *cis* and *trans* forms.




Fig. 3: Total Ion Current Chromatogram




Fig. 4: Typical SIM Mass Chromatograms for 0.1 ng/mg Concentration in Active Pharmaceutical Ingredients

First Edition: June, 2012



Shimadzu Corporation

www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

© Shimadzu Corporation, 2012